Annex Advisory Services LLC Has $1.56 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Annex Advisory Services cut its Medpace stake by 96.9% in the second quarter, selling 91,713 shares and retaining 2,943 shares worth approximately $1.56 million.
• Medpace reported a quarterly earnings beat, with EPS of $4.25 versus the $3.98 consensus and revenue of $707.33 million, up 17.2% year over year. Shares opened at $596.98, near the analyst consensus price target of $584.18.
• Analysts largely maintain a “Hold” consensus, while insiders have sold 54,231 shares worth about $30.2 million over the past three months.

Annex Advisory Services LLC decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 96.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,943 shares of the company's stock after selling 91,713 shares during the period. Annex Advisory Services LLC's holdings in Medpace were worth $1,559,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. AQR Capital Management LLC boosted its position in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock worth $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Franklin Resources Inc. increased its holdings in Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company's stock valued at $168,198,000 after purchasing an additional 183,645 shares during the last quarter. Norges Bank acquired a new position in Medpace in the fourth quarter valued at about $102,156,000. Finally, Goldman Sachs Group Inc. lifted its stake in Medpace by 92.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company's stock valued at $194,920,000 after buying an additional 166,654 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

MEDP has been the topic of a number of recent analyst reports. Wall Street Zen cut Medpace from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Jefferies Financial Group cut Medpace from a "buy" rating to a "hold" rating and upped their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. TD Cowen increased their price target on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Robert W. Baird lifted their price objective on shares of Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research note on Friday, July 24th. Finally, Truist Financial boosted their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $584.18.

Medpace Price Performance

Shares of Medpace stock opened at $596.98 on Thursday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The business has a 50-day moving average of $531.28 and a two-hundred day moving average of $491.78. The company has a market capitalization of $16.66 billion, a P/E ratio of 34.99, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. Medpace's revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company's stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares of the company's stock, valued at $37,790,400. This represents a 10.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 54,231 shares of company stock worth $30,187,908. Company insiders own 20.50% of the company's stock.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source